{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T08:16:04Z","timestamp":1770711364452,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This correspondence comments on a published article presenting a case of rhombencephalitis following SARS-CoV-2-vaccination with the mRNA vaccine BNT162b2 (Pfizer\/BioNTech). We also present the case of a 47-year-old man who developed Guillain-Barr\u00e9-syndrome and a fulminant encephalomyelitis 28\u00a0days after immunization with Ad26.COV2.S (Janssen\/Johnson &amp; Johnson). Based on the presented cases, we underscore the importance of clinical awareness for early recognition of overlapping neuroimmunological syndromes following vaccination against SARS-CoV-2. Additionally, we propose that that role of autoantibodies against angiotensin-converting enzyme 2 (ACE2) and the cell-surface receptor neuropilin-1, which mediate neurological manifestations of SARS-CoV-2, merit further investigation in patients presenting with neurological disorders following vaccination against SARS-CoV-2.<\/jats:p>","DOI":"10.1186\/s42466-022-00172-1","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T03:02:21Z","timestamp":1644289341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Guillain-Barr\u00e9 syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy"],"prefix":"10.1186","volume":"4","author":[{"given":"Maria Ioanna","family":"Stefanou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Karachaliou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Chondrogianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Moschovos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Bakola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aikaterini","family":"Foska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Melanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Andreadou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Voumvourakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilda","family":"Papathanasiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Boutati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0640-3797","authenticated-orcid":false,"given":"Georgios","family":"Tsivgoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"issue":"1","key":"172_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s42466-021-00156-7","volume":"3","author":"A Walter","year":"2021","unstructured":"Walter, A., & Kraemer, M. (2021). A neurologist\u2019s rhombencephalitis after comirnaty vaccination: A change of perspective. Neurological Research and Practice, 3(1), 56. https:\/\/doi.org\/10.1186\/s42466-021-00156-7","journal-title":"Neurological Research and Practice"},{"issue":"13","key":"172_CR2","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1021\/acschemneuro.0c00249","volume":"11","author":"A Torabi","year":"2020","unstructured":"Torabi, A., Mohammadbagheri, E., Akbari Dilmaghani, N., Bayat, A. H., Fathi, M., Vakili, K., et al. (2020). Proinflammatory cytokines in the olfactory mucosa result in COVID-19 induced anosmia. ACS Chemical Neuroscience, 11(13), 1909\u20131913. https:\/\/doi.org\/10.1021\/acschemneuro.0c00249","journal-title":"ACS Chemical Neuroscience"},{"issue":"16","key":"172_CR3","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1212\/wnl.0000000000012703","volume":"97","author":"KT Thakur","year":"2021","unstructured":"Thakur, K. T., Epstein, S., Bilski, A., Balbi, A., Boehme, A. K., Brannagan, T. H., et al. (2021). Neurologic safety monitoring of COVID-19 vaccines: Lessons from the past to inform the present. Neurology, 97(16), 767\u2013775. https:\/\/doi.org\/10.1212\/wnl.0000000000012703","journal-title":"Neurology"},{"key":"172_CR4","doi-asserted-by":"publisher","first-page":"103189","DOI":"10.1016\/j.msard.2021.103189","volume":"55","author":"I Lotan","year":"2021","unstructured":"Lotan, I., Romanow, G., & Levy, M. (2021). Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases. Mult Scler Relat Disord., 55, 103189. https:\/\/doi.org\/10.1016\/j.msard.2021.103189","journal-title":"Mult Scler Relat Disord."},{"issue":"12","key":"172_CR5","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","volume":"27","author":"M Patone","year":"2021","unstructured":"Patone, M., Handunnetthi, L., Saatci, D., Pan, J., Katikireddi, S. V., Razvi, S., et al. (2021). Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nature Medicine, 27(12), 2144\u20132153. https:\/\/doi.org\/10.1038\/s41591-021-01556-7","journal-title":"Nature Medicine"},{"key":"172_CR6","doi-asserted-by":"publisher","first-page":"653786","DOI":"10.3389\/fimmu.2021.653786","volume":"12","author":"GC Rom\u00e1n","year":"2021","unstructured":"Rom\u00e1n, G. C., Gracia, F., Torres, A., Palacios, A., Gracia, K., & Harris, D. (2021). Acute transverse myelitis (ATM): Clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222). Frontiers in Immunology, 12, 653786. https:\/\/doi.org\/10.3389\/fimmu.2021.653786","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"172_CR7","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1111\/ene.14860","volume":"28","author":"L Palaiodimou","year":"2021","unstructured":"Palaiodimou, L., Stefanou, M. I., Katsanos, A. H., Fragkou, P. C., Papadopoulou, M., Moschovos, C., et al. (2021). Prevalence, clinical characteristics and outcomes of Guillain-Barr\u00e9 syndrome spectrum associated with COVID-19: A systematic review and meta-analysis. European Journal of Neurology, 28(10), 3517\u20133529. https:\/\/doi.org\/10.1111\/ene.14860","journal-title":"European Journal of Neurology"},{"key":"172_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10785-2","author":"E Khan","year":"2021","unstructured":"Khan, E., Shrestha, A. K., Colantonio, M. A., Liberio, R. N., & Sriwastava, S. (2021). Acute transverse myelitis following SARS-CoV-2 vaccination: A case report and review of literature. Journal of Neurology. https:\/\/doi.org\/10.1007\/s00415-021-10785-2","journal-title":"Journal of Neurology"},{"key":"172_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05662-9","author":"RK Garg","year":"2021","unstructured":"Garg, R. K., & Paliwal, V. K. (2021). Spectrum of neurological complications following COVID-19 vaccination. Neurological Sciences. https:\/\/doi.org\/10.1007\/s10072-021-05662-9","journal-title":"Neurological Sciences"},{"key":"172_CR10","doi-asserted-by":"publisher","first-page":"577606","DOI":"10.1016\/j.jneuroim.2021.577606","volume":"358","author":"C Pagenkopf","year":"2021","unstructured":"Pagenkopf, C., & S\u00fcdmeyer, M. (2021). A case of longitudinally extensive transverse myelitis following vaccination against Covid-19. Journal of Neuroimmunology, 358, 577606. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577606","journal-title":"Journal of Neuroimmunology"},{"key":"172_CR11","doi-asserted-by":"publisher","first-page":"106887","DOI":"10.1016\/j.clineuro.2021.106887","volume":"208","author":"A Introna","year":"2021","unstructured":"Introna, A., Caputo, F., Santoro, C., Guerra, T., Ucci, M., Mezzapesa, D. M., et al. (2021). Guillain-Barr\u00e9 syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association? Clinical Neurology and Neurosurgery, 208, 106887. https:\/\/doi.org\/10.1016\/j.clineuro.2021.106887","journal-title":"Clinical Neurology and Neurosurgery"},{"issue":"6","key":"172_CR12","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1016\/j.jemermed.2021.07.062","volume":"61","author":"A Rossetti","year":"2021","unstructured":"Rossetti, A., Gheihman, G., O\u2019Hare, M., & Kosowsky, J. M. (2021). Guillain-Barr\u00e9 syndrome presenting as facial diplegia after COVID-19 vaccination: A case report. Journal of Emergency Medicine, 61(6), e141\u2013e145. https:\/\/doi.org\/10.1016\/j.jemermed.2021.07.062","journal-title":"Journal of Emergency Medicine"},{"key":"172_CR13","doi-asserted-by":"publisher","first-page":"3619131","DOI":"10.1155\/2021\/3619131","volume":"2021","author":"J Finsterer","year":"2021","unstructured":"Finsterer, J. (2021). Exacerbating Guillain-Barr\u00e9 syndrome eight days after vector-based COVID-19 vaccination. Case Reports in Infectious Diseases, 2021, 3619131. https:\/\/doi.org\/10.1155\/2021\/3619131","journal-title":"Case Reports in Infectious Diseases"},{"key":"172_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/bcr-2021-244125","volume":"14","author":"N McKean","year":"2021","unstructured":"McKean, N., & Chircop, C. (2021). Guillain-Barr\u00e9 syndrome after COVID-19 vaccination. BML Case Reports, 14, 7. https:\/\/doi.org\/10.1136\/bcr-2021-244125","journal-title":"BML Case Reports"},{"key":"172_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/bcr-2021-243629","volume":"14","author":"T Hasan","year":"2021","unstructured":"Hasan, T., Khan, M., Khan, F., & Hamza, G. (2021). Case of Guillain-Barr\u00e9 syndrome following COVID-19 vaccine. BML Case Reports, 14, 6. https:\/\/doi.org\/10.1136\/bcr-2021-243629","journal-title":"BML Case Reports"},{"issue":"16","key":"172_CR16","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1001\/jama.2021.16496","volume":"326","author":"EJ Woo","year":"2021","unstructured":"Woo, E. J., Mba-Jonas, A., Dimova, R. B., Alimchandani, M., Zinderman, C. E., & Nair, N. (2021). Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barr\u00e9 syndrome, February-July 2021. JAMA, 326(16), 1606\u20131613. https:\/\/doi.org\/10.1001\/jama.2021.16496","journal-title":"JAMA"},{"issue":"1","key":"172_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41541-021-00369-6","volume":"6","author":"FX Heinz","year":"2021","unstructured":"Heinz, F. X., & Stiasny, K. (2021). Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines, 6(1), 104. https:\/\/doi.org\/10.1038\/s41541-021-00369-6","journal-title":"NPJ Vaccines"},{"key":"172_CR18","doi-asserted-by":"publisher","first-page":"20738","DOI":"10.1038\/s41598-021-99401-x","volume":"11","author":"JS Schardt","year":"2021","unstructured":"Schardt, J. S., Pornnoppadol, G., Desai, A. A., Park, K. S., Zupancic, J. M., Makowski, E. K., et al. (2021). Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening. Science and Reports, 11, 20738. https:\/\/doi.org\/10.1038\/s41598-021-99401-x","journal-title":"Science and Reports"},{"issue":"8","key":"172_CR19","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1001\/jamaneurol.2020.2065","volume":"77","author":"AS Zubair","year":"2020","unstructured":"Zubair, A. S., McAlpine, L. S., Gardin, T., Farhadian, S., Kuruvilla, D. E., & Spudich, S. (2020). Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: A review. JAMA Neurology, 77(8), 1018\u20131027. https:\/\/doi.org\/10.1001\/jamaneurol.2020.2065","journal-title":"JAMA Neurology"},{"key":"172_CR20","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.17.209288","author":"A Moutal","year":"2020","unstructured":"Moutal, A., Martin, L. F., Boinon, L., Gomez, K., Ran, D., Zhou, Y., et al. (2020). SARS-CoV-2 Spike protein co-opts VEGF-A\/neuropilin-1 receptor signaling to induce analgesia. bioRxiv. https:\/\/doi.org\/10.1101\/2020.07.17.209288","journal-title":"bioRxiv."},{"issue":"6518","key":"172_CR21","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.abd2985","volume":"370","author":"L Cantuti-Castelvetri","year":"2020","unstructured":"Cantuti-Castelvetri, L., Ojha, R., Pedro, L. D., Djannatian, M., Franz, J., Kuivanen, S., et al. (2020). Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science, 370(6518), 856\u2013860.","journal-title":"Science"},{"issue":"1","key":"172_CR22","doi-asserted-by":"publisher","first-page":"e1009153","DOI":"10.1371\/journal.ppat.1009153","volume":"17","author":"BS Mayi","year":"2021","unstructured":"Mayi, B. S., Leibowitz, J. A., Woods, A. T., Ammon, K. A., Liu, A. E., & Raja, A. (2021). The role of neuropilin-1 in COVID-19. PLoS Pathogens., 17(1), e1009153.","journal-title":"PLoS Pathogens."},{"issue":"5","key":"172_CR23","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.3892\/mmr.2020.11510","volume":"22","author":"J Davies","year":"2020","unstructured":"Davies, J., Randeva, H. S., Chatha, K., Hall, M., Spandidos, D. A., Karteris, E., et al. (2020). Neuropilin-1 as a new potential SARS-CoV-2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID-19. Molecular Medicine Reports, 22(5), 4221\u20134226. https:\/\/doi.org\/10.3892\/mmr.2020.11510","journal-title":"Molecular Medicine Reports"},{"issue":"6518","key":"172_CR24","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1126\/science.abd3072","volume":"370","author":"JL Daly","year":"2020","unstructured":"Daly, J. L., Simonetti, B., Klein, K., Chen, K.-E., Williamson, M. K., Ant\u00f3n-Pl\u00e1garo, C., et al. (2020). Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science, 370(6518), 861\u2013865.","journal-title":"Science"},{"issue":"5","key":"172_CR25","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1073\/pnas.1008721108","volume":"108","author":"BD Solomon","year":"2011","unstructured":"Solomon, B. D., Mueller, C., Chae, W. J., Alabanza, L. M., & Bynoe, M. S. (2011). Neuropilin-1 attenuates autoreactivity in experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America, 108(5), 2040\u20132045. https:\/\/doi.org\/10.1073\/pnas.1008721108","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"20","key":"172_CR26","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1242\/jcs.190702","volume":"129","author":"Y Wang","year":"2016","unstructured":"Wang, Y., Cao, Y., Mangalam, A. K., Guo, Y., LaFrance-Corey, R. G., Gamez, J. D., et al. (2016). Neuropilin-1 modulates interferon-\u03b3-stimulated signaling in brain microvascular endothelial cells. Journal of Cell Science, 129(20), 3911\u20133921. https:\/\/doi.org\/10.1242\/jcs.190702","journal-title":"Journal of Cell Science"},{"key":"172_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/ijms22115992","volume":"22","author":"M Siri","year":"2021","unstructured":"Siri, M., Dastghaib, S., Zamani, M., Rahmani-Kukia, N., Geraylow, K. R., Fakher, S., et al. (2021). Autophagy, unfolded protein response, and neuropilin-1 cross-talk in SARS-CoV-2 infection: What can be learned from other coronaviruses. International Journal of Molecular Sciences, 22, 11. https:\/\/doi.org\/10.3390\/ijms22115992","journal-title":"International Journal of Molecular Sciences"},{"key":"172_CR28","doi-asserted-by":"publisher","first-page":"102683","DOI":"10.1016\/j.jaut.2021.102683","volume":"122","author":"AI Rodriguez-Perez","year":"2021","unstructured":"Rodriguez-Perez, A. I., Labandeira, C. M., Pedrosa, M. A., Valenzuela, R., Suarez-Quintanilla, J. A., Cortes-Ayaso, M., et al. (2021). Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. Journal of Autoimmunity, 122, 102683. https:\/\/doi.org\/10.1016\/j.jaut.2021.102683","journal-title":"Journal of Autoimmunity"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-022-00172-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-022-00172-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-022-00172-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T03:02:47Z","timestamp":1644289367000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-022-00172-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["172"],"URL":"https:\/\/doi.org\/10.1186\/s42466-022-00172-1","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,8]]},"assertion":[{"value":"5 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"On behalf of all authors, the corresponding author states that the patient provided written informed consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}